Estimated Savings Under the Medicare High-Value Drug List Model

JAMA Intern Med. 2024 Nov 1;184(11):1390-1392. doi: 10.1001/jamainternmed.2024.4846.

Authors

Christopher L Cai¹, Aaron S Kesselheim¹, Benjamin N Rome¹

Affiliation

¹ PORTAL (Program On Regulation, Therapeutics, And Law), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

PMID: 39312213
PMCID: PMC11420815 (available on 2025-09-23)
DOI: 10.1001/jamainternmed.2024.4846

No abstract available

Plain language summary

This cross-sectional study describes potential reductions in out-of-pocket costs for generic medications among Medicare beneficiaries.